Although lithium remains the preferred medication for bipolar disorders, new investigations suggest that only 60 to 80% of patients have a good response with a classical presentation. The antiepileptics carbamazepine and valproate are important alternatives. Several studies have shown that lithium, carbamazepine and valproate are effective in pure mania. Mixed mania and rapid cycling respond, however, well to valproate. One disadvantage of carbamazepine is its enzyme inducing property with the consequence of a decrease of plasma levels of other psychotropic medications and a worsening of psychopathology. First data indicate a good antimanic and antidepressive efficacy of the new antiepileptic drug lamotrigine.
Introduction
increased activity. Approximately 40-60% of manic patients suffer from this type of mania. Up to 50% of bipolar patients, however, have mixed (or dysphoric mania) which There is now substantial evidence that the mood stabilizers lithium, carbamazepine and valproate are effective is defined as an episode meeting the criteria both for mania and for a major depressive phase. Several investiin the treatment of acute episodes of mania. Less study data exist for the efficacy of these mood stabilizers in the gations indicate that lithium, carbamazepine and valproate are effective in pure mania. On the other hand, these management of bipolar (and unipolar) depression and in the prophylaxis of depressive phases [1] [2] [3] [4] . The knowledge results also establish that mixed mania responds well to valproate whereas lithium is relatively ineffective in mixed of several predictors of response for the different mood stabilizers would improve the total treatment response mania [1, [6] [7] [8] (table 1) .
A recently completed study from the European valproand eventually shorten the duration of hospitalization for the patients [5] .
ate acute mania study group [9] corroborates the results of the other cited studies. The aim of that investigation was to show that valproate-treated patients need less neuroleptics than placebo-treated patients. 136 patients were
Pure Mania vs. Mixed Mania enrolled in this multicenter, randomized, double-blind, placebo-controlled parallel group study. As a result the Pure (or euphoric or typical) mania is characterized by typical manic symptoms without depressive features, mean daily dose of concomitant neuroleptic medication expressed as mg haloperidol equivalents continuously dee.g. elevated mood, grandiosity, reduced sleep time and Kukopulos et al. (1980) open longitudinal study; 72% show low efficacy to lithium Calabrese et al. (1993) 101 patients with rapid cycling: marked acute and prophylactic antimanic effects, marked antimixed state effects and poor-to-moderate acute and prophylactic antidepressant effects creased in the valproate group from 14.3 mg at the begin-valproate [12, 13] . As a result the use of carbamazepine was associated with significant lower haloperidol plasma ning of the study to 8.1 mg after 3 weeks. In the placebo group the decline was from 12.0 mg to 10.8 mg (the levels and a worse clinical outcome (pPANSS-Score) compared to antipsychotic monotherapy ( fig. 2) . Valproate difference was statistically significant, p>0.0001; fig. 1 ). Patients scoring high for the dysphoria item (item 5) of had no significant effect on the plasma level and did not influence the psychopathology. the Young mania rating scale had an even more favorable outcome with valproate, with a decrease of the daily haloperidol equivalents from 13.9 at the beginning to 6.1 at the end of the study.
Rapid Cycling
Another new parallel-group, double-blind study with 179 patients indicates that depressive symptoms during Four or more depressive or manic phases in 1 year has been defined as rapid cycling bipolar disorder. It is a manic episode were associated with a poor antimanic response to lithium and with a better response to val-assumed that 13-20% of bipolar patients have rapid cycling [16] . In general, patients with bipolar rapid cycling proate [11] . The authors conclude that even a modest level of pretreatment depression-related symptoms is a have a lower response rate to lithium during both acute and prophylactic treatment [14, 15] . In an open longiturobust predictor of lithium nonresponse and is associated with a better response to valproate. Data concern-dinal study with 434 patients 72% showed a low efficacy of lithium treatment [17] . ing carbamazepine in pure or mixed mania are less clear because many of the clinical studies were not double Studies are not consistent concerning the efficacy of carbamazepine in rapid cycling [18, 19] . A metaanalyis blind or randomized which limits its interpretability [10] .
shows, however, that the response rate for carbamazepine is 32% for depression and 52% for mania which is worse A major disadvantage of carbamazepine is, however, its enzyme-inducing properties with the consequence that than the efficacy in a prospective study indicating a good effect for valproate in 42% of depressed and 73% of manic its own plasma levels (autoinduction) as well as plasma levels of concomitant psychotropic medication (heteroin-patients [16] . In summary, rapid cycling seems to be a likely predictor of less response to lithium and possibly duction) may decrease. In a recent controlled clinical trial with 30 patients with schizophrenia or schizoaffective carbamazepine compared to valproate.
A special problem is a possible drug-induced switching disorder three different groups were randomly assigned to 4 weeks of treatment with either haloperidol alone, from bipolar depression into mania. Whereas there are some discussions concerning a drug-induced switch into haloperidol with carbamazepine or with haloperidol with Fig. 1 . Decrease of the mean daily dose of haloperidol equivalents in the valproate group and the placebo group. According to Mü llerOerlinghausen and Retzow and the European valproate acute mania study group (1997) [9] . mania some hints in the literature indicate a cycle acceleration by the usage of antidepressant drugs [20] .
V
In summary, the studies so far suggest that valproate is useful in a broad spectrum of bipolar disorders and is and rapid cycling. Furthermore, all atypical types of According to Normann et al. [13] .
mania, e.g. mixed mania, rapid cycling, neurological cofactors and organic mania, respond less well to lithium. A major advantage of valproate is the fact that the drug Furthermore, lamotrigine also appears to be valuable in is well tolerated in an effective plasma level range from the prophylaxis of schizoaffective disorders [Erfurth et al., 50 to 125 g/ml [21] . Moreover, a dose loading with initial this issue]. oral doses of 20 mg/kg body weight has shown a rapid Moreover, recent single case reports suggest that gabaclinical improvement of psychopathology [22] .
pentin might also be useful in the treatment of mania.
In an open trial we treated 14 patients with acute mania with gabapentin in a dose range from 1,200 to 4,800
Lamotrigine and Gabapentin mg/day [25] . Six patients received gabapentin as add-on medication and 8 were treated with gabapentin alone. As Several open studies suggest an efficacy of the new a result, gabapentin was both effective and safe when antiepileptic drug lamotrigine not only in the treatment administered in combination with other drugs as lithium of mania but also in depressed states in bipolar patients or valproate. BRMAS scores decreased from 37.7 to 7.8 [23, 24] . Controlled double-blind studies are still ongoing. on day 21 in the add-on group and from 27.8 to 9.0 Concerning long-term prophylactic efficacy, an interest-in the monotherapy group. Four of 8 patients in the ing case of a patient with bipolar rapid cycling with monotherapy group dropped out due to a failure of effivalproate treatment reveals a drastic improvement after cacy. As these were the patients with the highest BRMAS the addition of lamotrigine [24] . In this case lamotrigine scores, it can be assumed that gabapentin might be useful up to 150 mg/day was added to valproate (2,700 mg/day). in patients with modest but not severe mania. A considerable improvement of the patient's condition was achieved several days after the beginning of lamotrigine coadministration and lasted over the total follow- 
